ALX Oncology Identifies CD47 as Predictive Biomarker for Evorpacept in HER2-Positive Breast Cancer
Event summary
- ALX Oncology's Phase 1b/2 trial data show CD47 expression predicts response to evorpacept + zanidatamab in HER2-positive breast cancer.
- Exploratory analysis reinforces CD47 as a biomarker, aligning with ASPEN-06 gastric cancer trial findings.
- Full biomarker dataset submitted for presentation at an upcoming scientific conference.
- Trial (NCT05027139) demonstrated 56% cORR and 7.4-month mPFS in heavily pretreated patients.
The big picture
ALX Oncology's findings position CD47 expression as a potential cornerstone for optimizing immuno-oncology treatments in HER2-positive cancers. This biomarker-driven approach could enhance patient selection and treatment efficacy, potentially reshaping the competitive landscape for CD47-targeting therapies. The data reinforce the company's strategic focus on leveraging biomarker insights to advance its pipeline in precision oncology.
What we're watching
- Biomarker Validation
- Whether CD47 expression can be consistently validated as a predictive biomarker across multiple HER2-positive cancer types.
- Clinical Translation
- The pace at which these findings will be incorporated into ongoing ASPEN-09-Breast Phase 2 trial and future patient selection strategies.
- Competitive Positioning
- How this biomarker-driven approach differentiates ALX Oncology's evorpacept from other CD47 inhibitors in development.
Our editorial coverage:
Related topics